Suppr超能文献

头孢泊肟酯在未感染患者肺实质和上皮衬液中的渗透情况。

Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients.

作者信息

Muller-Serieys C, Bancal C, Dombret M C, Soler P, Murciano G, Aubier M, Bergogne-Berezin E

机构信息

Department of Microbiology, Bichat-Claude Bernard University Hospital, Paris, France.

出版信息

Antimicrob Agents Chemother. 1992 Oct;36(10):2099-103. doi: 10.1128/AAC.36.10.2099.

Abstract

The pulmonary disposition of cefpodoxime was studied in 12 patients with pulmonary opacities after a single oral dose of 260 mg of cefpodoxime-proxetil, which is equivalent to 200 mg of cefpodoxime. Blood and lung tissue samples were collected during surgery, and bronchoalveolar lavage was carried out 3 h (group A) or 6 h (group B) after drug administration. Urea was used as an endogenous marker for measurement of the volume of epithelial lining fluid (ELF). Concentrations were measured by using a microbiological assay. The mean concentrations of cefpodoxime in plasma, ELF, and lung tissue were, respectively, 1.85 +/- 0.82 mg/liter, 0.22 +/- 0.13 mg/liter, and 0.89 +/- 0.80 mg/kg of body weight in group A and 1.40 +/- 1.25 mg/liter, 0.12 +/- 0.14 mg/liter, and 0.84 +/- 0.61 mg/kg in group B. Concentrations in lung parenchyma 6 h after dosing were at least equal to or above the MICs for 90% of the strains of most organisms commonly found in respiratory tract infections, whereas data for ELF suggest levels of drug insufficient to inhibit bacteria.

摘要

在12例肺部有混浊的患者中研究了头孢泊肟的肺部处置情况,这些患者单次口服260mg头孢泊肟酯(相当于200mg头孢泊肟)。在手术过程中采集血液和肺组织样本,并在给药后3小时(A组)或6小时(B组)进行支气管肺泡灌洗。使用尿素作为内源性标志物来测量上皮衬液(ELF)的体积。通过微生物测定法测量浓度。A组血浆、ELF和肺组织中头孢泊肟的平均浓度分别为1.85±0.82mg/升、0.22±0.13mg/升和0.89±0.80mg/千克体重,B组分别为1.40±1.25mg/升、0.12±0.14mg/升和0.84±0.61mg/千克。给药后6小时肺实质中的浓度至少等于或高于呼吸道感染中常见大多数菌株的90%的最低抑菌浓度(MIC),而ELF的数据表明药物水平不足以抑制细菌。

相似文献

1
Penetration of cefpodoxime proxetil in lung parenchyma and epithelial lining fluid of noninfected patients.
Antimicrob Agents Chemother. 1992 Oct;36(10):2099-103. doi: 10.1128/AAC.36.10.2099.
2
Concentrations of cefpodoxime in plasma and pleural fluid after a single oral dose of cefpodoxime proxetil.
J Antimicrob Chemother. 1990 Dec;26 Suppl E:41-6. doi: 10.1093/jac/26.suppl_e.41.
3
Concentrations of cefpodoxime in plasma and lung tissue after a single oral dose of cefpodoxime proxetil.
J Antimicrob Chemother. 1990 Dec;26 Suppl E:35-40. doi: 10.1093/jac/26.suppl_e.35.
4
Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil.
Antimicrob Agents Chemother. 1990 Jun;34(6):1094-9. doi: 10.1128/AAC.34.6.1094.
5
Concentrations of cefpodoxime in plasma and tonsillar tissue after a single oral dose of cefpodoxime proxetil.
J Antimicrob Chemother. 1990 Dec;26 Suppl E:47-51. doi: 10.1093/jac/26.suppl_e.47.
6
Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function.
Antimicrob Agents Chemother. 1992 Jan;36(1):126-31. doi: 10.1128/AAC.36.1.126.
7
A review of the pharmacokinetics of cefpodoxime proxetil.
Drugs. 1991;42 Suppl 3:13-21. doi: 10.2165/00003495-199100423-00005.
8
Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.
Antimicrob Agents Chemother. 1992 Apr;36(4):796-800. doi: 10.1128/AAC.36.4.796.
9
Disposition of cefpodoxime proxetil in hemodialysis patients.
J Clin Pharmacol. 1992 Nov;32(11):1038-44. doi: 10.1002/j.1552-4604.1992.tb03808.x.
10
Effect of food on absorption of cefpodoxime proxetil oral suspension in adults.
Antimicrob Agents Chemother. 1995 Jan;39(1):273-5. doi: 10.1128/AAC.39.1.273.

引用本文的文献

1
Biological Obstacles for Identifying - Correlations of Orally Inhaled Formulations.
Pharmaceutics. 2019 Jul 5;11(7):316. doi: 10.3390/pharmaceutics11070316.
2
Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.
Clin Pharmacokinet. 2011 Oct;50(10):637-64. doi: 10.2165/11594090-000000000-00000.
5
Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).
Antimicrob Agents Chemother. 2001 Nov;45(11):3104-8. doi: 10.1128/AAC.45.11.3104-3108.2001.
6
Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
Paediatr Drugs. 2001;3(2):137-58. doi: 10.2165/00128072-200103020-00006.
7
Clinical pharmacokinetics of newer cephalosporins.
Clin Pharmacokinet. 1995 May;28(5):361-84. doi: 10.2165/00003088-199528050-00003.

本文引用的文献

1
Pulmonary disposition of tobramycin.
Am Rev Respir Dis. 1983 May;127(5):563-5. doi: 10.1164/arrd.1983.127.5.563.
2
Uptake of antibiotics by human alveolar macrophages.
Am Rev Respir Dis. 1984 Jun;129(6):933-7. doi: 10.1164/arrd.1984.129.6.933.
4
Pulmonary disposition of roxithromycin (RU 28965), a new macrolide antibiotic.
Antimicrob Agents Chemother. 1987 Sep;31(9):1312-6. doi: 10.1128/AAC.31.9.1312.
5
Bronchoalveolar lavage.
Am Rev Respir Dis. 1987 Jan;135(1):250-63. doi: 10.1164/arrd.1987.135.1.250.
6
Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution.
J Appl Physiol (1985). 1986 Feb;60(2):532-8. doi: 10.1152/jappl.1986.60.2.532.
7
In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin.
Antimicrob Agents Chemother. 1987 Jul;31(7):1085-92. doi: 10.1128/AAC.31.7.1085.
8
Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone.
Antimicrob Agents Chemother. 1988 Dec;32(12):1896-8. doi: 10.1128/AAC.32.12.1896.
9
Penetration of ampicillin and sulbactam in the lower airways during respiratory infections.
Antimicrob Agents Chemother. 1990 Jun;34(6):958-62. doi: 10.1128/AAC.34.6.958.
10
The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins.
J Antimicrob Chemother. 1990 Apr;25(4):541-50. doi: 10.1093/jac/25.4.541.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验